Furthermore, we were the first to show that the CP40-KK, a newly identified analog of the selective C3 inhibitor CP40, could ameliorate the established PAH in the MCT-induced rat model, which therefore, potentiates it as an attractive therapeutic drug candidate that may complement existing treatment regimens to improve outcomes for PAH patients. The gene discussed is C3; the disease is pulmonary arterial hypertension.